SGPL1 and Alzheimer disease: Recent research has highlighted the potential of S1P in reducing Aβ accumulation, secretion, aggregation, and in attenuating the activity of β-site APP cleaving enzyme 1 (BACE1).10 - 12 Furthermore, deficiencies in SPL have been associated with accumulation of full-length APP and amyloidogenic C-terminal fragments,13 suggesting that modulating S1P levels could hold promise for AD therapy.